MGNX – Macrogenics Inc
MacroGenics, Inc.MGNX
$1.72Name : MacroGenics, Inc.
Sector : Healthcare
Industry: Biotechnology
Mark. Cap: $108,713,816.00
EPSttm : -0.57
MacroGenics, Inc.
$1.72
2.27%$0.04Float Short %
6.42
Margin Of Safety %
Put/Call OI Ratio
0.24
EPS Next Q Diff
0.42
EPS Last/This Y
-0.64
EPS This/Next Y
-1.07
Price
1.71
Target Price
3.75
Analyst Recom
2.5
Performance Q
8.18
Relative Volume
0.37
Beta
1.56
Ticker: MGNX
of 1
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
|---|---|---|---|---|---|
| 2025-09-08 | MGNX | 1.75 | 0.18 | 0.01 | 3776 |
| 2025-09-09 | MGNX | 1.73 | 0.17 | 0.00 | 3937 |
| 2025-09-10 | MGNX | 1.715 | 0.17 | 3.00 | 3941 |
| 2025-09-11 | MGNX | 1.67 | 0.18 | 0.00 | 3946 |
| 2025-09-12 | MGNX | 1.58 | 0.18 | 0.16 | 3947 |
| 2025-09-15 | MGNX | 1.5295 | 0.17 | 0.67 | 3980 |
| 2025-09-16 | MGNX | 1.47 | 0.17 | 0.07 | 3995 |
| 2025-09-17 | MGNX | 1.53 | 0.17138686131387 | 0 | 4012 |
| 2025-09-18 | MGNX | 1.727 | 0.17 | 0.35 | 4100 |
| 2025-09-19 | MGNX | 1.615 | 0.17 | 3.57 | 4245 |
| 2025-09-22 | MGNX | 1.74 | 0.23 | 0.00 | 4119 |
| 2025-09-23 | MGNX | 1.67 | 0.22 | 0.00 | 4213 |
| 2025-09-24 | MGNX | 1.72 | 0.25 | 4.93 | 4448 |
| 2025-09-25 | MGNX | 1.65 | 0.26 | 0.50 | 4582 |
| 2025-09-26 | MGNX | 1.73 | 0.27 | 0.11 | 4765 |
| 2025-09-29 | MGNX | 1.745 | 0.27 | 0.00 | 4795 |
| 2025-09-30 | MGNX | 1.68 | 0.27 | 0.00 | 4812 |
| 2025-10-01 | MGNX | 1.7 | 0.26 | 0.00 | 4867 |
| 2025-10-02 | MGNX | 1.705 | 0.26 | 0.06 | 4865 |
| 2025-10-03 | MGNX | 1.775 | 0.26 | 0.13 | 4880 |
| 2025-10-06 | MGNX | 1.77 | 0.25 | 0.00 | 5100 |
| 2025-10-07 | MGNX | 1.715 | 0.24 | 0.13 | 5340 |
| Date | Symbol | Last | P/C OI | P/C Vol | Total OI |
Current Page1 of 1
of 1
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
|---|---|---|---|---|---|
| 2025-09-08 | MGNX | 1.76 | -136.7 | - | -1.71 |
| 2025-09-09 | MGNX | 1.72 | -136.7 | - | -1.71 |
| 2025-09-10 | MGNX | 1.72 | -136.7 | - | -1.71 |
| 2025-09-11 | MGNX | 1.65 | -136.7 | - | -1.71 |
| 2025-09-12 | MGNX | 1.58 | -136.7 | - | -1.71 |
| 2025-09-15 | MGNX | 1.56 | -136.7 | - | -1.71 |
| 2025-09-16 | MGNX | 1.47 | -136.7 | - | -1.71 |
| 2025-09-17 | MGNX | 1.54 | -136.7 | - | -1.71 |
| 2025-09-18 | MGNX | 1.73 | -136.7 | - | -1.71 |
| 2025-09-19 | MGNX | 1.62 | -136.7 | - | -1.71 |
| 2025-09-22 | MGNX | 1.73 | -136.7 | - | -1.71 |
| 2025-09-23 | MGNX | 1.67 | -136.7 | - | -1.71 |
| 2025-09-24 | MGNX | 1.72 | -136.7 | - | -1.71 |
| 2025-09-25 | MGNX | 1.65 | -136.7 | - | -1.71 |
| 2025-09-26 | MGNX | 1.73 | -136.7 | - | -1.71 |
| 2025-09-29 | MGNX | 1.74 | -136.7 | - | -1.71 |
| 2025-09-30 | MGNX | 1.68 | -136.7 | - | -1.71 |
| 2025-10-01 | MGNX | 1.71 | -136.7 | - | -1.71 |
| 2025-10-02 | MGNX | 1.70 | -136.7 | - | -1.71 |
| 2025-10-03 | MGNX | 1.77 | -136.7 | - | -1.71 |
| 2025-10-06 | MGNX | 1.77 | -136.7 | - | -1.71 |
| 2025-10-07 | MGNX | 1.71 | -136.7 | - | -1.71 |
| Date | Ticker | Price | Current Quarter Growth Estimate | EBIT Estimation | Average EPS Estimate Current Year |
Current Page1 of 1
of 1
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
|---|---|---|---|---|
| 2025-09-08 | MGNX | 1.98 | -12.39 | 6.72 |
| 2025-09-09 | MGNX | 1.98 | -12.39 | 6.72 |
| 2025-09-10 | MGNX | 1.98 | -12.39 | 6.72 |
| 2025-09-11 | MGNX | 1.98 | -12.39 | 6.48 |
| 2025-09-12 | MGNX | 1.98 | -12.39 | 6.48 |
| 2025-09-15 | MGNX | 1.98 | -12.30 | 6.48 |
| 2025-09-16 | MGNX | 1.98 | -12.30 | 6.48 |
| 2025-09-17 | MGNX | 1.98 | -12.30 | 6.48 |
| 2025-09-18 | MGNX | 1.98 | -12.30 | 6.48 |
| 2025-09-19 | MGNX | 1.98 | -12.30 | 6.48 |
| 2025-09-22 | MGNX | 1.98 | -12.34 | 6.48 |
| 2025-09-23 | MGNX | 1.98 | -12.34 | 6.48 |
| 2025-09-24 | MGNX | 1.98 | -12.34 | 6.48 |
| 2025-09-25 | MGNX | 1.98 | -12.34 | 6.42 |
| 2025-09-26 | MGNX | 1.98 | -12.34 | 6.42 |
| 2025-09-29 | MGNX | 1.98 | -12.34 | 6.42 |
| 2025-09-30 | MGNX | 1.98 | -12.34 | 6.42 |
| 2025-10-01 | MGNX | 1.98 | -12.34 | 6.42 |
| 2025-10-02 | MGNX | 1.98 | -12.34 | 6.42 |
| 2025-10-03 | MGNX | 1.98 | -12.34 | 6.42 |
| 2025-10-06 | MGNX | 1.98 | -7.89 | 6.42 |
| 2025-10-07 | MGNX | 1.98 | -7.89 | 6.42 |
| Date | Ticker | Insider Transactions | Institutional Transactions | Float Short |
Current Page1 of 1
Last Quarter Act. EPS
-0.57
Avg. EPS Est. Current Quarter
-0.33
Avg. EPS Est. Next Quarter
-0.15
Insider Transactions
1.98
Institutional Transactions
-7.89
Beta
1.56
Average Sales Estimate Current Quarter
28
Average Sales Estimate Next Quarter
33
Fair Value
Quality Score
37
Growth Score
46
Sentiment Score
21
Actual DrawDown %
95.3
Max Drawdown 5-Year %
-97
Target Price
3.75
P/E
Forward P/E
PEG
P/S
0.66
P/B
2.33
P/Free Cash Flow
EPS
-0.57
Average EPS Est. Cur. Y
-1.71
EPS Next Y. (Est.)
-2.78
Target Price Estimates Raised
Target Price Estimates Lowered
Profit Margin
-21.99
Relative Volume
0.37
Return on Equity vs Sector %
-103.3
Return on Equity vs Industry %
-89.6
EPS 1 7Days Diff
EPS 1 30Days Diff
EBIT Estimation
MacroGenics, Inc.Sector: Healthcare
Industry: Biotechnology
Employees: 341
MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics to treat cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear cell gynecologic cancer which has completed phase 1 clinical trial; MGC026, an ADC that targets B7-H3 and delivers a novel topoisomerase I inhibitor (TOP1i)-based linker-payload; MGC028, an antibody-drug conjugates (ADC) that targets ADAM9 and delivers a novel TOP1i-based linker-payload for the treatment of solid tumors, which is in phase 1 clinical trials; MGC030, a ADC molecule for the treatment of solid tumors, which is in preclinical trials. It is also developing next generation T-cell engager programs. The company has collaborations with TerSera Therapeutics LLC; Incyte Corporation; and Gilead Sciences, Inc. MacroGenics, Inc. was incorporated in 2000 and is headquartered in Rockville, Maryland.
stock quote shares MGNX – Macrogenics Inc Stock Price stock today
news today MGNX – Macrogenics Inc stock forecast ,stock prediction 2023 2024 2025
marketwatch MGNX – Macrogenics Inc yahoo finance google finance
stock history MGNX – Macrogenics Inc invest stock market
stock prices MGNX premarket after hours
ticker MGNX fair value insiders trading